EUVIMEDEUVIMED entdecken
Klinische Studie

Cost and cost-effectiveness analysis of a digital diabetes prevention program: results from the PREDICTS trial

Tzeyu L Michaud iD, Kathryn E Wilson iD, Jeffrey A Katula, Wen You, Paul A Estabrooks

Translational Behavioral Medicine · 01.07.2023 · 13 (7) · 501-510

DOI: 10.1093/tbm/ibad008 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Translational Behavioral Medicine, online erschienen am 21.02.2023. Verfasst von Tzeyu L Michaud und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Promotion, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA. Hauptthemen laut MEDLINE: Cost-Effectiveness Analysis, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Omada Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although technology-assisted diabetes prevention programs (DPPs) have been shown to improve glycemic control and weight loss, information are limited regarding relevant costs and their cost-effectiveness. To describe a retrospective within-trial cost and cost-effectiveness analysis (CEA) to compare a digital-based DPP (d-DPP) with small group education (SGE), over a 1-year study period. The costs were summarized into direct medical costs, direct nonmedical costs (i.e., times that participants spent engaging with the interventions), and indirect costs (i.e., lost work productivity costs). The CEA was measured by the incremental cost-effectiveness ratio (ICER). Sensitivity analysis was performed using nonparametric bootstrap analysis. Over 1 year, the direct medical costs, direct nonmedical costs, and indirect costs per participant were $4,556, $1,595, and $6,942 in the d-DPP group versus $4,177, $1,350, and $9,204 in the SGE group. The CEA results showed cost savings from d-DPP relative to SGE based on a societal perspective. Using a private payer perspective for d-DPP, ICERs were $4,739 and $114 to obtain an additional unit reduction in HbA1c (%) and weight (kg), and were $19,955 for an additional unit gain of quality-adjusted life years (QALYs) compared to SGE, respectively. From a societal perspective, bootstrapping results indicated that d-DPP has a 39% and a 69% probability, at a willingness-to-pay of $50,000/QALY and $100,000/QALY, respectively, of being cost-effective. The d-DPP was cost-effective and offers the prospect of high scalability and sustainability due to its program features and delivery modes, which can be easily translated to other settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost-Effectiveness AnalysisDiabetes Mellitus, Type 2HumansCost-Benefit AnalysisRetrospective StudiesWeight Loss

Stichwörter der Autor:innen

absenteeismdigital healtheconomic evaluationlifestyle interventionpresenteeismwork productivity

Autor:innen und Institutionen

  • Department of Health Promotion, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
  • Center for Reducing Health Disparities, College of Public Health, University of Nebraska Medical Center, Omaha, NE, USA.
  • Department of Kinesiology and Health, College of Education & Human Development, Georgia State University, Atlanta, GA, USA.
  • Center for the Study of Stress, Trauma, and Resilience, College of Education and Human Development, Georgia State University, Atlanta, GA, USA.
  • Department of Health and Exercise Science, Wake Forest University, Winston-Salem, NC, USA.
  • Department of Public Health Sciences, University of Virginia, Charlottesville, VA, USA.

ORCID-Profile: Tzeyu L Michaud, Kathryn E Wilson

Förderung

  • Omada Health

Zitieren

APA

Michaud, T. L., Wilson, K. E., Katula, J. A., You, W., & Estabrooks, P. A. (2023). Cost and cost-effectiveness analysis of a digital diabetes prevention program: results from the PREDICTS trial. Translational Behavioral Medicine, 13(7), 501-510. https://doi.org/10.1093/tbm/ibad008

Vancouver

Michaud TL, Wilson KE, Katula JA, You W, Estabrooks PA. Cost and cost-effectiveness analysis of a digital diabetes prevention program: results from the PREDICTS trial. Translational Behavioral Medicine. 2023;13(7):501-510. doi:10.1093/tbm/ibad008

BibTeX
@article{Michaud2023,
  author = {Michaud, Tzeyu L and Wilson, Kathryn E and Katula, Jeffrey A and You, Wen and Estabrooks, Paul A},
  title = {Cost and cost-effectiveness analysis of a digital diabetes prevention program: results from the PREDICTS trial},
  journal = {Translational Behavioral Medicine},
  year = {2023},
  volume = {13},
  number = {7},
  pages = {501--510},
  doi = {10.1093/tbm/ibad008}
}
Kostenlos starten →